Medline MDLN
Medline Inc. is a supplier of medical supplies and equipment for the healthcare sector, operating as a large-scale manufacturer and distributor, selling to hospitals, clinics, and other healthcare providers. Medline shows revenue growth of 11.6% and earnings growth of 262%, but its financial health is fragile: net debt/EBITDA of 3.95, operating margin of only 0.82%, and ROE of 4.93%. Valuation (P/E 43.38) is demanding and momentum is negative (-15.29%), suggesting caution.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Medline Inc. is a supplier of medical supplies and equipment for the healthcare sector, operating as a large-scale manufacturer and distributor, selling to hospitals, clinics, and other healthcare providers. Medline shows revenue growth of 11.6% and earnings growth of 262%, but its financial health is fragile: net debt/EBITDA of 3.95, operating margin of only 0.82%, and ROE of 4.93%. Valuation (P/E 43.38) is demanding and momentum is negative (-15.29%), suggesting caution.
Score by category
| Category | Score |
|---|---|
| Financial health | 3.4 |
| Quality / Moat | 2.7 |
| Valuation | 3.9 |
| Growth | 8.5 |
| Dividend | 1.5 |
| Momentum | 2.4 |
| Risk & Context | 4.3 |
OVERALL SCORE: 3.9/10
Context and risks
Moderate regulatory risk in the US for the healthcare sector (pricing pressure on medical devices). No direct relevant geopolitical exposure.
News considered in the analysis
- Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play — Noticia inmobiliaria sobre un tercero (Astellas), sin impacto directo en Medline.
- Medline (MDLN) Could Be 29% Undervalued As Its Pullback Tests Sentiment — Análisis de valoración que sugiere que la acción está infravalorada tras la caída; refuerza la tesis de valor, aunque es opinión de analista.
- Medline (MDLN) Stock Could Trade Below Fair Value As Shares Fell 22% — Señala que la caída del 22% ha dejado el precio por debajo del valor razonable; consistente con la nota de valoración moderada.
- Medline (MDLN) Slips Amid Broader MedTech Weakness — Caída en línea con el sector MedTech; ya reflejada en el momentum y en el precio.
- Jim Cramer Names Medline (MDLN) a Sleeper Compounder — Respaldo público de Jim Cramer; puede atraer interés minorista, pero no cambia los fundamentales.
Verdict: Hold; wait for the company to demonstrate margin improvement and debt reduction before considering entry.
Main risk: High leverage (ND/EBITDA 3.95) combined with a minimal operating margin (0.82%) makes Medline vulnerable to rising rates and any pricing pressure in the healthcare sector.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →